Patents Represented by Attorney, Agent or Law Firm Randolph T. Apple
  • Telomerase
    Patent number: 6309867
    Abstract: The present invention is directed to novel telomerase nucleic acids and amino acids. In particular, the present invention is directed to nucleic acid and amino acid sequences encoding various telomerase protein subunits and motifs, including the 123 kDa and 43 kDa telomerase protein subunits of Euplotes aediculatus, and related sequences from Schizosaccharomyces, Saccharomyces sequences, and human telomerase. The present invention is also directed to polypeptides comprising these telomerase protein subunits, as well as functional polypeptides and ribonucleoproteins that contain these subunits.
    Type: Grant
    Filed: October 29, 1999
    Date of Patent: October 30, 2001
    Assignee: University Technology Corporation
    Inventors: Thomas R. Cech, Toru Nakamura
  • Telomerase
    Patent number: 6261836
    Abstract: The present invention is directed to telomerase nucleic acids and amino acids. In particular, the present invention is directed to nucleic acid and amino acid sequences encoding various telomerase protein subunits and motifs, including the 123 kDa and 43 kDa telomerase protein subunits of Euplotes aediculatus, and related sequences from Schizosaccharomyces, Saccharomyces sequences, and human telomerase. The present invention is also directed to polypeptides comprising these telomerase protein subunits, as well as functional polypeptides and ribonucleoproteins that contain these subunits.
    Type: Grant
    Filed: May 9, 1997
    Date of Patent: July 17, 2001
    Assignees: Geron Corporation, University Technology Corporation
    Inventors: Thomas R. Cech, Joachim Lingner, Toru Nakamura, Karen B. Chapman, Gregg B. Morin, Calvin B. Harley, William H. Andrews
  • BCRF1 antagonists for treating epstein-barr virus infections
    Patent number: 5756342
    Abstract: A method of treating EBV infections is provided. The method comprises administering an effective amount of an monoclonal antibody antagonist to the EBV protein, BCRF1. Preferably, the antagonist is a blocking monoclonal antibody specific for BCRF1, or a fragment or binding composition derived therefrom.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: May 26, 1998
    Assignee: Schering Corporation
    Inventor: Kevin W. Moore